In February 2026, the U.S. Department of Health and Human Services announced the reclassification of approximately 14 peptides from FDA Category 2 — which had prohibited compounding since 2023 — back to Category 1, restoring legal access through licensed compounding pharmacies under physician prescription. BPC-157 and TB-500 (Thymosin Beta-4) were both specifically named in this reclassification. For research institutions and peptide manufacturers sourcing these compounds, the implications are direct: procurement demand is resuming, and the quality standards for raw material documentation are more important than ever.
This guide covers what the reclassification actually means, what the peer-reviewed research shows for each compound individually, why researchers study them in combination, and what B2B buyers need to verify when sourcing BPC-157 and TB-500 raw materials.
The FDA Reclassification: What Changed and What It Means
To understand the significance of the February 2026 announcement, it helps to understand the regulatory history. In 2023, the FDA classified 19 peptides as Category 2, effectively prohibiting licensed compounding pharmacies from preparing them. The stated basis was insufficient safety and efficacy data to support compounding. The practical consequence, acknowledged by policymakers, was a shift of demand to unregulated gray-market sources — the opposite of the intended outcome.
The February 2026 reclassification reversed this for approximately 14 of those 19 compounds. BPC-157 and TB-500 are among the peptides now restored to Category 1. This is a critical distinction to understand clearly:
| Category | Meaning | BPC-157 / TB-500 Status |
| FDA-Approved Drug | Completed full clinical trial process; approved for specific indication | Not applicable — neither compound is an FDA-approved drug |
| Category 1 | May be compounded by licensed pharmacies under physician prescription; no approved equivalent exists | Current status (as of February 2026) |
| Category 2 | Prohibited from compounding; applies when FDA determines insufficient safety/efficacy data | Status from 2023–2026 (now reversed) |
For B2B buyers, the reclassification does not change the research-use status of either compound. What it does is restore a significant channel of legitimate end-user demand — compounding pharmacies — that had been effectively cut off for two years. For research institutions, both compounds remained accessible throughout; the reclassification primarily affects the compounding pharmacy supply chain.
BPC-157: Mechanism and Research Evidence
BPC-157 (Body Protection Compound-157; CAS 137525-51-0) is a synthetic pentadecapeptide — a 15-amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a naturally occurring protein found in human gastric juice. Unlike many research peptides, BPC-157 has no endogenous full-length equivalent; it is a stable synthetic fragment studied extensively in animal models across multiple organ systems.
The research base for BPC-157 is unusually broad. Key areas with published preclinical evidence include:
| Research Area | Proposed Mechanism | Key Model Systems |
| Gastrointestinal mucosal repair | Upregulation of growth factors (EGF, FGF); promotion of angiogenesis in gastric and intestinal tissue | Rat gastric ulcer, colitis, IBD models |
| Tendon and ligament healing | Stimulation of tendon outgrowth, cell survival, and directional migration; modulation of VEGFR2/FAK signaling | Rat Achilles tendon transection, MCL injury models |
| Skeletal muscle repair | Acceleration of myocyte regeneration following crush injury; anti-inflammatory effects at injury site | Rat gastrocnemius muscle injury models |
| Neuroprotection / CNS | Modulation of dopaminergic and serotonergic systems; interaction with NO-synthase pathways | Rat models of traumatic brain injury, spinal cord injury |
| Bone healing | Stimulation of osteoblast proliferation; interaction with growth factor pathways relevant to bone remodeling | Rat femoral fracture models |
A landmark review by Sikiric et al. in Current Pharmaceutical Design documented BPC-157’s multi-organ protective effects across more than two decades of preclinical research, with particular focus on its remarkable stability in gastric acid — a property that distinguishes it from most biologically active peptides and enables oral delivery studies in animal models [1]. The same group published extensive evidence for BPC-157’s tendon-healing effects, including a mechanistic study demonstrating that BPC-157 promotes tendon outgrowth and cell survival through specific signaling pathways involved in angiogenesis and cell migration [2].
It is important to note that BPC-157’s research base is almost entirely preclinical. Published human clinical trial data is limited. For research institutions designing protocols, this context is essential: the compound’s therapeutic potential is supported by a large body of animal research, but translation to human outcomes remains an active area of investigation rather than established clinical fact.
TB-500 (Thymosin Beta-4): Mechanism and Research Evidence
TB-500 is the synthetic form of Thymosin Beta-4 (Tβ4; CAS 77591-33-4), a naturally occurring 43-amino acid polypeptide found in virtually all mammalian cells. Unlike BPC-157, which is a synthetic fragment with no natural full-length counterpart, TB-500 mirrors an endogenous peptide with well-characterized biological roles — including actin sequestration, cell migration promotion, and tissue repair coordination.
Thymosin Beta-4 was originally identified as a thymic hormone involved in T-cell differentiation, but its functional significance is now understood to extend well beyond the immune system. Key research areas:
| Research Area | Proposed Mechanism | Key Evidence |
| Cardiac repair and regeneration | Activation of epicardial progenitor cells; promotion of new cardiomyocyte formation after myocardial injury | Smart et al., Nature 2007 (PMID 17108971) — landmark study on epicardial progenitor activation |
| Wound healing and angiogenesis | Promotion of endothelial cell migration and tube formation; upregulation of MMP-2 for tissue remodeling | Multiple in vitro and murine wound models; reviewed in Goldstein et al. 2012 [5] |
| Anti-inflammatory activity | Downregulation of NF-κB pathway; inhibition of inflammatory cytokine production | Preclinical models of acute and chronic inflammation |
| Hair follicle activation | Stimulation of hair follicle stem cells; promotion of telogen-to-anagen transition | Murine hair growth models; alopecia research |
| Neuroprotection | Promotion of neuronal survival; anti-apoptotic signaling following CNS injury | Rodent models of traumatic brain injury and stroke |
Crockford’s comprehensive review in Expert Opinion on Biological Therapy positioned Thymosin Beta-4 as a multifunctional regenerative peptide with particular promise for cardiovascular, wound-healing, and neurological applications [4]. Goldstein et al. further documented its role in promoting multi-tissue repair through coordinated effects on cell migration, inflammation, and angiogenesis [5]. The cardiac progenitor activation data from Smart et al. in Nature — demonstrating that Tβ4 can activate dormant epicardial progenitor cells to generate new cardiomyocytes after myocardial infarction in mouse models — remains one of the most cited findings in regenerative medicine peptide research [6].
Unlike BPC-157, Thymosin Beta-4 has some human clinical trial data, primarily in wound healing contexts. While these trials are limited in size and scope, they provide a stronger translational basis for certain research applications compared to BPC-157’s exclusively preclinical evidence base.
BPC-157 and TB-500: Complementary Mechanisms
Research institutions studying tissue repair and regeneration often source both BPC-157 and TB-500 as part of the same experimental framework. The rationale is mechanistic: the two compounds operate through distinct but non-overlapping pathways, with tissue targets that complement rather than duplicate each other.
| Property | BPC-157 | TB-500 (Thymosin Beta-4) |
| Origin | Synthetic fragment; no natural full-length counterpart | Synthetic form of endogenous 43-AA polypeptide |
| Molecular weight | ~1,419.5 g/mol (15 AA) | ~4,963.5 g/mol (43 AA) |
| Primary tissue targets | GI mucosa, tendon, ligament, muscle, neural tissue | Cardiac tissue, vascular endothelium, wound beds, hair follicle, neural tissue |
| Key mechanism | Angiogenesis promotion, growth factor upregulation, NO-synthase interaction | Actin sequestration, epicardial progenitor activation, NF-κB inhibition |
| Anti-inflammatory activity | Indirect (via tissue repair acceleration and NO pathway) | Direct (NF-κB pathway downregulation, cytokine suppression) |
| Human clinical data | Very limited; predominantly preclinical | Limited; some wound-healing trials |
| FDA Category (Feb 2026) | Category 1 (reclassified) | Category 1 (reclassified) |
The practical rationale for combination protocols is straightforward: BPC-157 targets local tissue repair (particularly GI, musculoskeletal, and neural) through signaling pathways that promote growth factor expression and cell survival at injury sites, while TB-500 operates more systemically — particularly through vascular remodeling, cardiac progenitor activation, and direct anti-inflammatory cytokine modulation. In multi-tissue injury models, these mechanisms are additive rather than redundant.
It should be noted that published data specifically on BPC-157 and TB-500 in combination is limited. Researchers designing combination protocols should treat the combination as an area of active investigation with mechanistic rationale rather than an established protocol with defined clinical outcomes. COA documentation for each compound separately remains essential regardless of the experimental design.
Demand Outlook After the Reclassification
The February 2026 reclassification has direct procurement implications for B2B buyers. Several demand dynamics are worth tracking:
Compounding pharmacy restocking. Pharmacies that suspended BPC-157 and TB-500 procurement during the Category 2 period are rebuilding raw material inventories. For suppliers with established inventory positions, this represents a near-term demand surge. Buyers rebuilding supply chains should confirm current lead times and available lot quantities before committing to patient pipeline timelines.
Research institution pipeline expansion. The reclassification, combined with the ongoing interest in tissue repair and regenerative medicine applications, has increased the number of institutions designing new BPC-157 and TB-500 protocols. Institutions planning multi-month animal studies need consistent batch-to-batch quality — making supplier documentation (COA, batch traceability) a selection criterion rather than an afterthought.
Elevated quality scrutiny. The 2023–2026 Category 2 period created a gray market, and concern about unverified raw material quality has increased among quality managers at compounding pharmacies and research institutions alike. Buyers are more likely than before the ban to request COA documentation before order commitment and to specifically ask for MS identity confirmation alongside HPLC purity data.
What to Verify When Sourcing BPC-157 and TB-500 Raw Materials
For B2B buyers sourcing BPC-157 and TB-500 in the current market, the following documentation parameters represent the minimum standard for a qualified supplier relationship:
| Parameter | BPC-157 Standard | TB-500 Standard |
| Purity (HPLC) | ≥98% minimum; ≥99% recommended for compounding | ≥98% minimum; ≥99% recommended for compounding |
| Identity confirmation | MS confirming MW ~1,419.5 g/mol and correct sequence | MS confirming MW ~4,963.5 g/mol and 43-AA sequence |
| Batch traceability | Unique batch number on COA linked to production records | Unique batch number on COA linked to production records |
| Appearance | White lyophilized powder; no visible discoloration or clumping | White lyophilized powder; no visible discoloration or clumping |
| Storage conditions | −20°C, sealed, protect from light and moisture | −20°C, sealed, protect from light and moisture |
| COA availability | Available before order commitment on request | Available before order commitment on request |
One additional consideration specific to the post-reclassification period: the gray market that developed during the 2023–2026 ban introduced a larger number of low-documentation suppliers into the market. MS identity confirmation — not just HPLC purity — is particularly important now because HPLC purity measures percentage of the dominant peak, but cannot confirm that the dominant peak is actually the correct peptide. A batch that is 99% pure but incorrectly synthesized will show high HPLC purity while delivering zero biological activity. MS confirmation is the only way to verify the compound is structurally correct.
Sourcing BPC-157 and TB-500 from Vitaconin
Vitaconin supplies BPC-157 and TB-500 as lyophilized powder raw materials, serving research institutions and peptide manufacturers in the US, EU, and globally. Every batch ships with full COA documentation including HPLC purity data and MS identity confirmation. MOQ starts at 1g for both compounds.
Browse our full peptide catalog:
Lyophilized Peptide Powders
Request a B2B quote or COA preview for BPC-157, TB-500 and related peptide raw materials. Vitaconin can provide purity documentation, packaging details and lead-time confirmation for qualified bulk inquiries.
Frequently Asked Questions
Q: Are BPC-157 and TB-500 now fully legal in the United States?
As of February 2026, both compounds have been reclassified as Category 1 peptides, meaning they may be compounded by licensed compounding pharmacies under a physician prescription. They are not FDA-approved drugs and have not completed full clinical trial programs. For research use, neither compound requires compounding pharmacy involvement — they can be sourced directly as research raw materials.
Q: What is the difference between TB-500 and Thymosin Beta-4?
TB-500 is the synthetic form of the naturally occurring polypeptide Thymosin Beta-4 (Tβ4). They share the identical 43-amino acid sequence. The name “TB-500” was originally used in equine medicine and has become common in research and compounding contexts. When sourcing, look for CAS 77591-33-4 and MS confirmation of the 43-AA sequence regardless of which name is used.
Q: Can BPC-157 and TB-500 be ordered together?
Yes. Vitaconin supplies both compounds independently with individual COA documentation. Researchers designing combination protocols can order separate batches with separate batch-specific COAs, which is generally required for research protocol documentation regardless of whether the compounds are used sequentially or in parallel.
Q: What purity grade is required for compounding pharmacy use vs. research use?
For most research applications, ≥98% HPLC-verified purity is the baseline minimum. For compounding pharmacy applications where documentation is submitted as part of quality systems or regulatory filings, ≥99% with MS identity confirmation is the more common requirement. Vitaconin supplies BPC-157 and TB-500 at ≥99% purity standard.
Q: How should lyophilized BPC-157 and TB-500 be stored?
Both compounds should be stored at −20°C in sealed containers, protected from light and moisture. Shelf life for properly stored lyophilized powder is 24 months. Once reconstituted, stability decreases significantly — follow the COA-specified reconstitution and storage protocol for each batch.
Disclaimer: This article is intended for B2B informational purposes for research institutions, compounding pharmacy professionals, and peptide manufacturers. It does not constitute medical advice. All peptide applications require appropriate regulatory compliance in the applicable jurisdiction.
References
[1] Sikiric P, et al. Stable Gastric Pentadecapeptide BPC-157: Novel Therapy in Gastrointestinal Tract. Curr Pharm Des. 2011;17(16):1612–32. PMID: 21548867
[2] Chang CH, et al. The Promoting Effect of Pentadecapeptide BPC-157 on Tendon Healing Involves Tendon Outgrowth, Cell Survival, and Cell Migration. J Appl Physiol. 2011;110(3):774–80. PMID: 21148341
[3] Sikiric P, et al. Brain-Gut Axis and Pentadecapeptide BPC-157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857–865. PMID: 27012953
[4] Crockford D. Thymosin Beta4: a Multifunctional Regenerative Peptide. Basic Properties and Clinical Applications. Expert Opin Biol Ther. 2010;10(8):1175–88. PMID: 20536466
[5] Goldstein AL, et al. Thymosin β4: a Multi-Functional Regenerative Peptide. Expert Opin Biol Ther. 2012;12(1):37–51. PMID: 22107186
[6] Smart N, et al. De Novo Cardiomyogenesis Performed by Thymosin Beta-4 Regulation of Epicardial Progenitors. Nature. 2007;445(7124):177–82. PMID: 17108971
[7] HHS / FDA. Compounded Drug Policy Update — Category 1 Peptide Reclassification. February 27, 2026. fda.gov/drugs/human-drug-compounding